Compare AbCellera Biologics Inc (ABCL) vs Carparts.Com Inc (PRTS) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

CarParts.com (PRTS) trades at $6.14, down 0.65% on the day, following a recent 10:1 reverse stock split that helped it regain Nasdaq compliance. The stock shows a bearish technical signal with negative cash flow and net losses, though it has beaten earnings estimates for three consecutive quarters. Recent developments include a new $25 million credit facility and the launch of a co-branded Mastercard, signaling efforts to stabilize operations and enhance customer financing options.

Despite persistent losses and negative cash flow, PRTS maintains a low P/S ratio of 0.07 and has analyst support with 60% buy ratings. The primary risk is sustained profitability challenges amid declining revenue, but cost discipline and new financial tools may provide a path to recovery if execution improves.